Patents are fortresses of new drugs. The patent layout of Enbrel is quite impressive: the span from the first application in 1995 to the patent expiration in 2029 reaches 34 years. Such unrepeatable success has extended the life of Enbrel and stopped the biosimilars. This article gives a brief overview of Enbrel and Amgen’s patent protection therefor.
